Hexagon Capital Partners LLC Buys 984 Shares of Sanofi (NASDAQ:SNY)

Hexagon Capital Partners LLC raised its holdings in Sanofi (NASDAQ:SNY) by 24.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,993 shares of the company’s stock after buying an additional 984 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Sanofi were worth $248,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Altrius Capital Management Inc increased its holdings in Sanofi by 1.7% during the fourth quarter. Altrius Capital Management Inc now owns 135,311 shares of the company’s stock worth $6,729,000 after buying an additional 2,318 shares during the last quarter. Transcend Capital Advisors LLC increased its holdings in Sanofi by 5.7% during the fourth quarter. Transcend Capital Advisors LLC now owns 5,730 shares of the company’s stock worth $285,000 after buying an additional 307 shares during the last quarter. Unique Wealth Strategies LLC purchased a new stake in Sanofi during the fourth quarter worth about $577,000. Atria Wealth Solutions Inc. increased its holdings in Sanofi by 7.9% during the fourth quarter. Atria Wealth Solutions Inc. now owns 16,370 shares of the company’s stock worth $814,000 after buying an additional 1,205 shares during the last quarter. Finally, Wynn Capital LLC purchased a new position in shares of Sanofi in the fourth quarter worth about $251,000. 10.04% of the stock is owned by institutional investors.

Sanofi Trading Up 0.3 %

Shares of NASDAQ SNY traded up $0.17 during mid-day trading on Wednesday, hitting $49.40. The stock had a trading volume of 203,051 shares, compared to its average volume of 2,003,169. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a 1 year low of $42.63 and a 1 year high of $55.93. The business has a 50 day moving average price of $47.82 and a two-hundred day moving average price of $48.25. The firm has a market cap of $124.96 billion, a P/E ratio of 24.71, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The business had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. On average, equities analysts anticipate that Sanofi will post 4.11 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a $1.478 dividend. This represents a yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio is presently 73.87%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. Morgan Stanley began coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price for the company. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.